Clinical Trial Update: An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing vedolizumab IV to adalimumab SC in ulcerative colitis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED | Results posted: 2019-10-10